LEADER 00000cam  2200000 i 4500 
001    ocn859375019 
003    OCoLC 
005    20140219183554.0 
008    130930s2014    nyua     b    001 0 eng   
010      2013039646 
016 7  101618151|2DNLM 
019    852226358|a869297999 
020    9781451655667|qhardback 
020    1451655665|qhardback 
020    |z9781451655674 (pbk.) 
020    |z1451655673 (pbk.) 
035    (OCoLC)859375019 
035    (OCoLC)859375019|z(OCoLC)852226358|z(OCoLC)869297999 
040    DNLM/DLC|beng|erda|cDLC|dIG#|dBTCTA|dBDX|dNLM|dJAG|dYDXCP
       |dIEB|dBUR|dWHP 
043    n-us--- 
049    WHPP 
050 04 RA401.A3|bW47 2014 
060 10 QV 736 AA1 
082 00 338.4/76151|223 
100 1  Werth, Barry,|eauthor. 
245 14 The antidote :|binside the world of new pharma /|cBarry 
       Werth. 
250    First Simon & Schuster hardcover edition. 
264  1 New York :|bSimon & Schuster,|c2014. 
300    x, 435 pages :|billustrations ;|c25 cm 
336    text|2rdacontent 
337    unmediated|2rdamedia 
338    volume|2rdacarrier 
504    Includes bibliographical references (pages 401-416) and 
       index. 
520    In 1989, the charismatic Joshua Boger left Merck, then 
       America's most admired business, to found a drug company 
       that would challenge industry giants and transform health 
       care. Journalist Barry Werth described the company's 
       tumultuous early days during the AIDS crisis in The 
       Billion-Dollar Molecule, a celebrated classic of science 
       and business journalism. Now he returns to tell the story 
       of Vertex's bold endurance and eventual success. The 
       pharmaceutical business is America's toughest and one of 
       its most profitable. It's riskier and more rigorous at 
       just about every stage than any other business, from the 
       towering biological uncertainties inherent in its mission 
       to treat disease; to the 30-to-1 failure rate in bringing 
       out a successful medicine; to the multibillion-dollar cost
       of ramping up a successful product; to operating in the 
       world's most regulated industry, matched only by nuclear 
       power. Werth captures the full scope of Vertex's 25-year 
       drive to deliver breakthrough medicines.--From publisher 
       description. 
610 20 Vertex Pharmaceuticals Incorporated. 
610 22 Vertex Pharmaceuticals Incorporated. 
650  0 Drugs|xMarketing. 
650  0 Pharmaceutical industry|zUnited States. 
650 12 Drug Industry|zUnited States. 
650 22 Drug Industry|xhistory|zUnited States. 
650 22 History, 20th Century|zUnited States. 
650 22 History, 21st Century|zUnited States. 
650 22 Technology, Pharmaceutical|zUnited States. 
914    MID.b23022449 
994    02|bWHP